These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17878961)

  • 1. Molecule of the month. Paliperidone.
    Drug News Perspect; 2007 Jun; 20(5):333. PubMed ID: 17878961
    [No Abstract]   [Full Text] [Related]  

  • 2. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
    Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.
    Jones A
    J Psychiatr Ment Health Nurs; 2008 Dec; 15(10):792-9. PubMed ID: 19012670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone extended-release for the treatment of schizophrenia.
    Marino J; Caballero J
    Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paliperidone overdose in a patient with schizophrenia.
    Chang JP; Huang CC; Su KP
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):418. PubMed ID: 19995588
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].
    Rusconi AC; Carlone C; Muscillo M; Piccione M
    Riv Psichiatr; 2009; 44(4):267-72. PubMed ID: 20066799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
    Pani L; Marchese G
    Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paliperidone (Invega) for schizophrenia.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):21-3. PubMed ID: 17351558
    [No Abstract]   [Full Text] [Related]  

  • 10. Behavioral stimulation associated with risperidone initiation.
    Byerly MJ; Greer RA; Evans DL
    Am J Psychiatry; 1995 Jul; 152(7):1096-7. PubMed ID: 7540799
    [No Abstract]   [Full Text] [Related]  

  • 11. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
    Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
    Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.
    Vázquez-Bourgon J; Rodríguez-Rodríguez P; Gómez-Ruíz E; Artal J; Crespo-Facorro B
    Ann Clin Psychiatry; 2014 Nov; 26(4):301-2. PubMed ID: 25401718
    [No Abstract]   [Full Text] [Related]  

  • 13. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
    Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
    Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug for schizophrenia.
    FDA Consum; 2007; 41(2):6. PubMed ID: 17590895
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.
    Han C; Lee SJ; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):650-1. PubMed ID: 21163319
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
    Amatniek J; Canuso CM; Deutsch SI; Henderson DC; Mao L; Mikesell C; Rodriguez S; Sheehan J; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):8-20. PubMed ID: 23428785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics.
    Schreiner A; Lahaye M; Peuskens J; Naber D; Dilbaz N; Millet B; Franco MA; Rancans E; Turczynski J; Smeraldi E; Lara E; Neznanov NG
    Expert Opin Pharmacother; 2014 Apr; 15(5):593-603. PubMed ID: 24491033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
    Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
    Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.